Randomized, controlled and single center clinical trial of Jifafang in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005789

Enrollment

Unknown

Registered

2022-03-30

Start date

2022-04-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute exacerbation of chronic obstructive pulmonary disease

Interventions

Test group:Basic treatment of Western Medicine (oxygen therapy, antibiotics, bronchodilators, expectorants, hormones, noninvasive ventilation, etc.) + JiFafang

Control group:Basic treatment of Western Medicine (oxygen therapy, antibiotics, bronchodilators, expectorants, hormones, noninvasive ventilation, etc.)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria of western medicine for acute exacerbation of chronic obstructive pulmonary disease according to the guidline of GOLD in 2022; 2.Hospitalized patients by emergency department with acute exacerbation within 3 days; 3.with age between 18 and 80 years old; 4.Agree to sign informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients who require invasive mechanical ventilation; 2.Complicated with a severe tumor, unstable coronary heart disease, abnormal liver and kidney function, cerebrovascular accident, and other diseases; 3.Those with known or suspected history of alcohol or drug abuse; 4.Patients with mental disorders who are unable to actively cooperate with treatment; 5.Patients with severe intellectual or cognitive impairments;? 6.Patients with a history of allergies to related drugs.? 7.Those who have participated in other clinical trials within the past 3 months; 8.Those who are judged by the investigator to be unsuitable to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Noninvasive oxygen saturation;Lung signs (wheezing, phlegm);Modified British medical research council(mMRC);	—

Secondary

Measure	Time frame
TCM syndrome score;The use of antibiotics (dose and duration);Chronic Obstructive Pulmonary Disease assessment(CAT);length of hospital stay;The use of glucocorticoid (dose and duration);Chest Dr or CT;Pulmonary function;Arterial blood gas analysis;outine blood test;	—

Countries

China

Contacts

Public ContactWu Jianghua

2416389799@qq.com18382191655

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026